Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3210404 | 0.82 | DRD2 (0.51) | RAB9ACNR1CNR2 | |
| SCHEMBL2125396 | 0.79 | MEN1 (0.55) | KMT2APAK1DRD4MEN1 | |
| SCHEMBL16009077 | 0.76 | OPRM1 (0.42) | — | |
| SCHEMBL25533157 | 0.75 | HPGD (0.52) | KMT2AGAAMEN1 | |
| SCHEMBL26911669 | 0.75 | OPRM1 (0.49) | — | |
| SCHEMBL3282038 | 0.74 | — | — | |
| SCHEMBL17698998 | 0.73 | ALDH1A1 (0.53) | KMT2AGAACNR2MEN1 | |
| SCHEMBL29998807 | 0.73 | P2RY12 (0.44) | KMT2AGAACNR1CNR2MEN1 | |
| SCHEMBL4016152 | 0.73 | HRH4 (0.44) | RAB9APAK1EGLN1 | |
| SCHEMBL23108183 | 0.73 | KMT2A (0.46) | KMT2AGAARAB9APAK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372843-B2 | Quinolines useful as modulators of ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-7683066-B2 | Isoquinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | KCNQ1, KCNQ2, KCNQ5 | KMT2A 1962/4885GAA 1480/4885RAB9A 1238/4885 |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNQ5 | KMT2A 1962/4885GAA 1480/4885RAB9A 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.